AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

AXB

60.5

+0.83%↑

JPM

291.11

-1.03%↓

BAC

45.52

-0.68%↓

WFC

77.92

+0.5%↑

MS

140.6

-0.51%↓

Search

TPG Specialty Lending Inc

Cerrado

SectorFinanzas

23.77 0.08

Resumen

Variación precio

24h

Actual

Mínimo

23.49

Máximo

23.94

Métricas clave

By Trading Economics

Ingresos

-14M

37M

Ventas

49M

114M

P/B

Media del Sector

12.693

25.916

Rentabilidad por dividendo

8.51

Margen de beneficio

32.44

EBITDA

-17M

64M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+0.96% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

8.51%

3.70%

Fecha Próximo Dividendo

29 sept 2025

Próxima Fecha de Ex Dividendo

15 sept 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

279M

2.3B

Apertura anterior

23.69

Cierre anterior

23.77

Noticias sobre sentimiento de mercado

By Acuity

20%

80%

29 / 536 Clasificación en Finance

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

TPG Specialty Lending Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

4 ago 2025, 21:42 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 ago 2025, 21:21 UTC

Ganancias
Principales Movimientos del Mercado

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 ago 2025, 20:45 UTC

Ganancias

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 ago 2025, 19:15 UTC

Principales Movimientos del Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 ago 2025, 23:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 ago 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Rise on Fed Stimulus Hopes

4 ago 2025, 23:28 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

4 ago 2025, 23:28 UTC

Charlas de Mercado

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 ago 2025, 21:30 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 ago 2025, 21:21 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 ago 2025, 21:18 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 ago 2025, 20:25 UTC

Charlas de Mercado

India Hits Back Over Russian Oil Purchases -- Market Talk

4 ago 2025, 20:25 UTC

Ganancias

Transocean 2Q Loss $938M >RIG

4 ago 2025, 20:25 UTC

Ganancias

Transocean 2Q Loss/Shr $1.06 >RIG

4 ago 2025, 20:18 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 ago 2025, 20:15 UTC

Ganancias

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 ago 2025, 20:13 UTC

Ganancias

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 ago 2025, 20:09 UTC

Ganancias

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 ago 2025, 20:06 UTC

Ganancias

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 ago 2025, 19:41 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 ago 2025, 19:28 UTC

Charlas de Mercado

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 ago 2025, 19:07 UTC

Charlas de Mercado

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 ago 2025, 18:27 UTC

Charlas de Mercado

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparación entre iguales

Cambio de precio

TPG Specialty Lending Inc Esperado

Precio Objetivo

By TipRanks

0.96% repunte

Estimación a 12 meses

Media 24.14 USD  0.96%

Máximo 25 USD

Mínimo 23 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para TPG Specialty Lending Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

7

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

20.83 / 21.65Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

29 / 536 Clasificación en Finanzas

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de TPG Specialty Lending Inc

Sixth Street Specialty Lending, Inc. (NYSE: TSLX) is a business development company. The fund provides senior secured loans (first-lien, second-lien, and unitranche), unsecured loans, mezzanine debt, and investments in corporate bonds and equity securities and structured products, non-control structured equity, and common equity with a focus on co-investments for organic growth, acquisitions, market or product expansion, restructuring initiatives, recapitalizations, and refinancing. The fund invests in business services, software & technology, healthcare, energy, consumer & retail, manufacturing, industrials, royalty related businesses, education, and specialty finance. It seeks to finance and lending to middle market companies principally located in the United States. The fund invests in companies with enterprise value between $50 million and $1 billion or more and EBITDA between $10 million and $250 million. The transaction size is between $15 million and $350 million. The fund invests across the spectrum of the capital structure and can arrange syndicated transactions of up to $500 million and hold sizeable positions within its credits.